Sentences with phrase «immunotherapy at»

Increased sales of and referrals for allergy skin tests and immunotherapy at assigned physicians» offices.

Several recent studies have shown that bacteria that naturally lives in and on the human body was as effective as immunotherapy at controlling the spread and growth of cancer.

Mackall leads the Parker Institute for Cancer Immunotherapy at Stanford, which supports the Stanford University Cancer Immunotherapy Program.

Dr. David Maloney, medical director for cellular immunotherapy at Fred Hutch and the Bezos Family Immunotherapy Clinic, talks about the promise of new therapies.

«I do think that it is a very amazing time in our field,» said Jedd D. Wolchok, associate director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering and one of the researchers in that study.

Dr. Jedd D. Wolchok is the chief of the Melanoma and Immunotherapeutics Service, the Lloyd J. Old / Virginia and Daniel K. Ludwig Chair in Clinical Investigation, and director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

Each of these grants supports clinical trials with our proprietary technology through the Center for Immunotherapy at RPCI in Buffalo, New York.

He is also Professor and Chair of the Department of Gynecologic Oncology, the M. Steven Piver Endowed Professor of Gynecologic Oncology at RPCI, and the Executive Director of the Center for Immunotherapy at RPCI.

is the Director of the Vector Development and Production Facility and the Associate Director of the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI).

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University.

Drew Pardoll, director of the Bloomberg - Kimmel Institute for Cancer Immunotherapy at Hopkins, and top researcher Suzanne L. Topalian took the unusual step of consulting with the cancer geneticists who worked one floor up.

For more information about T - Cell Immunotherapy at the Lineberger Comprehensive Cancer Center, please click here.

It was based on the research of Jim Allison, Ph.D., chair of Immunology, executive director of the immunotherapy platform and director of the Parker Institute for Cancer Immunotherapy at MD Anderson.

Wherry, together with his colleagues in the Parker Institute for Cancer Immunotherapy at Penn, are involved in multiple checkpoint - related trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.

«Checkpoint inhibitors are one of the most exciting recent advances for cancers, but the mechanism by which most patients become resistant to these therapies has been a mystery,» says Victor E. Velculescu, M.D., Ph.D., program leader in the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and professor of oncology.

The introduction of CRISPR, which is simpler and more efficient than other techniques, will probably accelerate the race to get gene - edited cells into the clinic across the world, says Carl June, who specializes in immunotherapy at the University of Pennsylvania in Philadelphia and led one of the earlier studies.

Maus - a former Penn faculty member who is now the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center and an assistant professor of Medicine at Harvard Medical School - is the senior author on the study.

His additional appointments include: head of the Swim Across America / Ludwig Collaborative Laboratory; associate director of the Ludwig Center for Cancer Immunotherapy; and director of the Parker Institute for Cancer Immunotherapy at MSK.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

My next career step was to accept a 6 - month position, which was then extended by an additional year, to establish a translational research laboratory for cancer immunotherapy at the Gustave Roussy Cancer Campus, a major nonprofit health care, research, and teaching institution in Paris.

«It will be much more powerful than the antibodies,» says Timothy Chan, who does clinical research in immunotherapy at Memorial Sloan Kettering Cancer Center in New York City.

After completing his Ph.D. in 2002 and staying on at ICL for a 2 - year postdoc, Barroso took a senior scientist position in cancer immunotherapy at GSK.

Dr. Hegde is a director and global franchise biomarker lead for cancer immunotherapy at Genentech / Roche.

«Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning.»

June, a professor in immunotherapy at the University of Pennsylvania, described recent triumphs in cancer research that have now been used to treat more than 300 children with leukemia, all of whom remain in remission.

On 29 September, AAAS hosted a lively online discussion on Reddit's «Ask Me Anything» (AMA) forum on implicit bias in science — a discussion Smith joined, along with Shirley Malcom, AAAS» director of Education and Human Resources programs, Caleph B. Wilson, a biomedical scientist with Cellectis, a biopharmaceutical company, and Avery Posey, Jr., an instructor in the Center for Cellular Immunotherapies at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Antoni Ribas, who researches immunotherapies at the Ronald Reagan UCLA Medical Center, said these reports should not change patients» and doctors» approach to immunotherapy.

Pioneering CAR T - cell therapy researcher Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania's Perelman School of Medicine and a co-director of the Parker Institute for Cancer Immunotherapy, delivered the keynote address at the Conference on Cell and Gene Therapy for HIV Cure at Fred Hutch.

Not exact matches

His family history is part of the connect - the - dots Parker plays without end, reading late into the night, swimming in medical papers, diving into conversations with researchers of any stripe — discussing malarial vectors with Sir Richard Feachem at UCSF and checkpoint inhibitors with Jim Allison, a groundbreaking immunotherapy researcher at MD Anderson in Houston.

In the most recent of these reports (in the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy above.

And when Ziskin's breast cancer had reemerged with brutal efficiency after a long remission, Parker had managed to get her into a last - ditch immunotherapy protocol at the Hutch, the famed Fred Hutchinson Cancer Research Center in Seattle — chartering private planes at his own expense to shepherd her back and forth from Los Angeles.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

Dr. Peter Kiener has substantial experience in both biologics and immunotherapy, and was most recently the Chief Scientific Officer at Sucampo, which was acquired by Mallinckrodt in February 2018 for approximately $ 1.2 billion.

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.

Cancer immunotherapies, or treatments that use the body's immune system to fight cancerous cells, were once again the most hotly anticipated drug class at the conference.

He argued that an industry - wide collaborative effort would hasten more targeted, personalized, and effective cancer treatments at a time when innovative new medications like immunotherapies are taking flight.

«We have decided not to move forward with the ROCKET trial or JCAR015 at this time, even though it generated important learnings for us and the immunotherapy field,» Juno president and CEO Hans Bishop said yesterday in a statement.

The company's CAR T - cell cancer immunotherapy furthest in development at present is JCAR017.

Dr. Fong is also co-director and medical director of the Parker Institute of Cancer Immunotherapy (PICI) at UCSF.

Dr. Fong is also the site principal investigator at UCSF for the NCI - sponsored Cancer Immunotherapy Trials Network (CITN).

Now, immunotherapy is at the forefront in oncology as a leading therapeutic which has been shown to cure cancer in previously untreatable patients.

After his pitch at the finals, an audience member representing an international investment group approached him, ultimately leading to Cerullo co-founding a company now working to bring a cancer immunotherapy to market.

Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.

«We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors,» said Benjamin Greenbaum, PhD, the senior author, who is affiliated with the departments of Medicine, Hematology and Medical Oncology, Pathology, and Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

We have so much more biology to understand when it comes to immunotherapy and patient response at a molecular level.»

Judith Gasson, senior associate dean for research at the David Geffen School of Medicine at UCLA and director of the Jonsson Cancer Center, said researchers have long hoped to develop an effective and lasting immunotherapy to fight cancer.

Debunked at the time, his treatments laid the groundwork for modern immunotherapy.

At Mayo, some immunologists work on basic research and others lean more toward the clinical applications of immunotherapy.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

Doug Mahoney's lab at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way.